About
Braveheart Bio
BRVE.US
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Profile
- Company Name
- Braveheart Bio, Inc.
- Market
- NasdaqGM
- Founded
- Industry
- --
- Fiscal Year End
- --
- Website
- www.braveheart.bio